Back

Epigenetic repression by SAHA leads to cardio-protection in anthracycline-induced long-term cardiotoxicity

20 June 2025 (13:10 - 14:10)
Organised by: Logo
Congress Presentation Part of: Insights into anthracycline-induced cardiotoxicity and treatment perspectives Research and New Technology CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Ms Benay Eksi

University Hospital Heidelberg, Heidelberg (Germany)

9 More presentations in this session

Presentation thumbnail
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
Doctor V. Quagliariello (Naples, IT)
Abstract Slides
Presentation thumbnail
Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after doxorubicin treatment
Associate Professor L. Lehmann (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Cardiac troponin autoantibodies in breast cancer patients receiving adjuvant cardiotoxic chemotherapy: the PRADA study
Ms H. Junes (Turku, FI)
Abstract Slides
Presentation thumbnail
Cardioprotective effects of the flavonoid quercetin against doxorubicin-Induced cardiotoxicity in H9c2 cardiomyoblasts
Doctor N. Chong (Nottingham, GB)
Abstract Slides
Presentation thumbnail
Exploring the cardioprotective efficacy of roflumilast as potential cAMP regulator against experimental epirubicin-induced myocardial injury: insights into oxidative stress and apoptosis.
Slides

Access the full session

Session thumbnail
Insights into anthracycline-induced cardiotoxicity and treatment perspectives

The Event

Event poster

ESC Cardio-Oncology 2025

20 June 2025 13:10 CET
You may be interested in
thumbnail
Congress Presentation
Anthracycline exposure alters the response to future cardiac stress response driven by FOXK1
thumbnail
Congress Presentation
Unveiling doxorubicin-induced cardiotoxicity: into the heart with single-cell resolution
thumbnail
Congress Presentation
In vitro platform to model anthracycline-induced cardiotoxicity and evaluate cardioprotective agents in human -induced pluripotent stem cells-derived cardiomyocytes

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources